Another trial is a phase I/II study of adoptive immunotherapy for advanced MUC1∗ positive BC using autologous T cells designed to express either a chimeric antigen receptor (CAR), huMNC2-CAR44, or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1∗). The gene discussed is MUC1; the disease is breast cancer.